LifeMD Narrows Losses but Misses EBITDA Targets Amid GLP-1 Transition — LifeMD, Inc.

Event summary

LifeMD reported Q2 2026 revenue of $47.3M, within guidance but with an adjusted EBITDA loss of $3.5M, improving 21% sequentially.
95% of new weight management patients now use branded GLP-1 therapies, marking the end of the transition from compounded medications.
Weight Management Program subscribers grew to 108,000, with total active subscribers increasing 20% year-over-year to 356,000.
Launched a telehealth co-marketing collaboration with Halozyme’s Antares Pharma for XYOSTED®, a once-weekly testosterone auto-injector.

The big picture

LifeMD’s Q2 results reflect the challenges of transitioning to branded GLP-1 therapies while managing customer acquisition costs. The company is positioning itself for long-term growth through strategic partnerships and a focus on higher LTV subscribers. The telehealth sector continues to evolve, with virtual care providers balancing profitability against scaling subscriber bases.

What we're watching

Profitability Timing: Whether LifeMD can sustain its sequential EBITDA improvements and return to positive adjusted EBITDA in the second half of 2026.
Partnership Impact: How the XYOSTED® collaboration with Halozyme’s Antares Pharma will contribute to revenue growth and operational efficiency.
Subscriber Retention: The pace at which LifeMD can convert new patients into longer-duration subscription plans, improving lifetime value.